Theralase Releases Q122 Interim Financial Statements
TORONTO, May 30, 2022 (GLOBE NEWSWIRE) — Theralase ® Technologies Inc. (“ Theralase ” or the “ Company ”) ( TSXV: TLT ) ( OTCQB: TLTFF ), a clinical stage…
Source: financialpost.com
Page 4 - Study Sites News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Study Sites. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Study Sites Today - Breaking & Trending Today
Effect of Intra-arterial Alteplase vs Placebo Following Successful Thrombectomy on Functional Outcomes in Patients With Large Vessel Occlusion Acute Ischemic Stroke: The CHOICE Randomized Clinical Trial | Cerebrovascular Disease | JAMA
This randomized clinical trial assesses the effect of intra-arterial alteplase infusion vs placebo on functional outcomes (modified Rankin Scale scores) among p
Source: jamanetwork.com
Frontiers | Estimating Benefits of Nature-based Solutions: Diverging Values From Choice Experiments With Time or Money Payments
Institute for Environmental Studies (IVM), Vrije Universiteit, Amsterdam, Netherlands Nature-based solutions (NBS) provide a promising means to a climate resilient future. To guide investments in NBS, stated preference studies have become a common tool to evaluate the benefits of NBS in developing countries. Due to subsistence lifestyles and generally lower incomes, SP studies in developing countries increasingly use time payments as an alternative to the traditionally implemented money payments. It remains unclear, however, how time values should be converted into money values, how the payme...
Source: frontiersin.org
Theralase Technologies Inc.: Theralase Releases Quarterly Newsletter
Theralase Technologies Inc.: Theralase Releases Quarterly Newsletter ® Technologies Inc. (" TSXV:TLT)( OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (" PDC") and associated drug formulations to safely and effectively destroy various cancers, bacteria and viruses has released the Company's Quarterly Newsletter (" Newsletter") which provides updates on the previous quarter and progress on the Phase II Non-Muscle Invasive Bladder Cancer (" NMIBC") Clinical Study (" Highlights from the Newsletter: Clinic...
Source: finanznachrichten.de
Theralase Technologies Inc.: Theralase Launches Fifth Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study
Theralase Technologies Inc.: Theralase Launches Fifth Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study Theralase" or the " TSXV:TLT)( OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (" PDC") and their associated drug formulations used to safely and effectively destroy various cancers, bacteria and viruses announced today that University of Wisconsin Health-Madison (" UWH") has received site Institutional Review Board (" IRB") approval to commence a pivotal Phase II Non-Muscle Invas...
Source: finanznachrichten.de